AURINIA PHARMACEUTICALS INC's ticker is AUPH and the CUSIP is 05156V102. A total of 128 filers reported holding AURINIA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.03 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $1,890,383 | -69.0% | 377,322 | -44.4% | 0.01% | -56.2% |
| Q4 2023 | $6,102,772 | +34.4% | 678,840 | +16.2% | 0.02% | +6.7% |
| Q3 2023 | $4,540,648 | +27.8% | 584,382 | +59.2% | 0.02% | +36.4% |
| Q2 2023 | $3,553,460 | +0.3% | 367,093 | +13.5% | 0.01% | -15.4% |
| Q1 2023 | $3,543,719 | +159.1% | 323,332 | +2.1% | 0.01% | +333.3% |
| Q4 2022 | $1,367,695 | -60.9% | 316,596 | -32.0% | 0.00% | -57.1% |
| Q3 2022 | $3,502,000 | -25.5% | 465,689 | -0.4% | 0.01% | 0.0% |
| Q2 2022 | $4,701,000 | -1.1% | 467,740 | +21.8% | 0.01% | +40.0% |
| Q1 2022 | $4,753,000 | +623.4% | 383,945 | +1236.0% | 0.01% | +400.0% |
| Q4 2021 | $657,000 | -47.1% | 28,738 | -48.8% | 0.00% | 0.0% |
| Q3 2021 | $1,241,000 | -66.0% | 56,087 | -80.1% | 0.00% | -75.0% |
| Q2 2021 | $3,650,000 | +74.1% | 281,651 | +74.4% | 0.00% | +33.3% |
| Q1 2021 | $2,097,000 | -52.3% | 161,473 | -49.2% | 0.00% | -62.5% |
| Q4 2020 | $4,397,000 | -13.0% | 317,956 | -7.3% | 0.01% | -50.0% |
| Q3 2020 | $5,054,000 | +15.5% | 343,093 | +27.4% | 0.02% | -20.0% |
| Q2 2020 | $4,375,000 | +38.1% | 269,231 | +23.3% | 0.02% | -23.1% |
| Q1 2020 | $3,167,000 | -8.4% | 218,274 | +27.9% | 0.03% | +8.3% |
| Q4 2019 | $3,459,000 | +866.2% | 170,723 | +155.0% | 0.02% | +700.0% |
| Q3 2019 | $358,000 | +342.0% | 66,956 | +446.8% | 0.00% | +200.0% |
| Q2 2019 | $81,000 | +189.3% | 12,246 | +180.9% | 0.00% | – |
| Q1 2019 | $28,000 | -92.1% | 4,359 | -91.7% | 0.00% | -100.0% |
| Q4 2018 | $356,000 | -53.6% | 52,253 | -54.8% | 0.00% | -50.0% |
| Q3 2018 | $767,000 | +70.8% | 115,489 | +44.7% | 0.01% | +50.0% |
| Q2 2018 | $449,000 | -41.1% | 79,790 | -45.7% | 0.00% | -50.0% |
| Q1 2018 | $762,000 | -26.0% | 146,851 | -35.4% | 0.01% | +14.3% |
| Q4 2017 | $1,030,000 | -37.3% | 227,265 | -13.2% | 0.01% | -53.3% |
| Q3 2017 | $1,642,000 | +13.8% | 261,863 | +11.2% | 0.02% | 0.0% |
| Q2 2017 | $1,443,000 | +271.0% | 235,467 | +343.9% | 0.02% | +200.0% |
| Q1 2017 | $389,000 | – | 53,051 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACT CAPITAL MANAGEMENT, LLC | 188,500 | $4,311,000 | 3.12% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 334,500 | $7,647,000 | 1.70% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 131,760 | $3,013,000 | 1.49% |
| NEA Management Company, LLC | 3,069,834 | $70,207,000 | 1.42% |
| Berry Street Capital Management LLP | 575,000 | $13,151,000 | 1.36% |
| Melqart Asset Management (UK) Ltd | 916,321 | $20,956,000 | 1.06% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 100,000 | $2,287,000 | 0.93% |
| HighMark Wealth Management LLC | 50,499 | $1,155,000 | 0.73% |
| Artal Group S.A. | 1,000,000 | $22,870,000 | 0.62% |
| Vigilare Wealth Management | 34,925 | $799,000 | 0.47% |